Abstract
Percutaneous coronary intervention has become a standard-of-care procedure in patients with acute and chronic coronary syndromes, in which coronary stent technology is commonly used. In this updated mini-review article, we list and summarize the characteristics of contemporary coronary drug-eluting and coated stents in 2023.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bangalore S, Toklu B, Patel N, Feit F, Stone GW. Newer-generation ultrathin strut drug-eluting stents versus older second-generation thicker strut drug-eluting stents for coronary artery disease. Circulation. 2018;138:2216–26.
Iannaccone M, Gatti P, Barbero U, Bassignana A, Gallo D, de Benedictis M, et al. Impact of strut thickness and number of crown and connectors on clinical outcomes on patients treated with second-generation drug eluting stent. Catheter Cardiovasc Interv. 2020;96:1417–22.
Nakazawa G, Shinke T, Ijichi T, Matsumoto D, Otake H, Torii S, et al. Comparison of vascular response between durable and biodegradable polymer-based drug-eluting stents in a porcine coronary artery model. EuroIntervention. 2014;10:717–23.
El-Hayek G, Bangalore S, Casso Dominguez A, Devireddy C, Jaber W, Kumar G, et al. Meta-analysis of randomized clinical trials comparing biodegradable polymer drug-eluting stent to second-generation durable polymer drug-eluting stents. JACC Cardiovasc Interv. 2017;10:462–73.
Kobayashi T, Sotomi Y, Suzuki S, Suwannasom P, Nakatani S, Morino Y, et al. Five-year clinical efficacy and safety of contemporary thin-strut biodegradable polymer versus durable polymer drug-eluting stents: a systematic review and meta-analysis of 9 randomized controlled trials. Cardiovasc Interv Ther. 2020;35:250–8.
Saito S, Krucoff MW, Nakamura S, Mehran R, Maehara A, Al-Khalidi HR, et al. Japan-United States of America Harmonized Assessment by Randomized Multicentre Study of OrbusNEich’s Combo StEnt (Japan-USA HARMONEE) study: primary results of the pivotal registration study of combined endothelial progenitor cell capture and drug-eluting stent in patients with ischaemic coronary disease and non-ST-elevation acute coronary syndrome. Eur Heart J. 2018;39:2460–8.
Madhavan MV, Kirtane AJ, Redfors B, Généreux P, Ben-Yehuda O, Palmerini T, et al. Stent-related adverse events > 1 year after percutaneous coronary intervention. J Am Coll Cardiol. 2020;75:590–604.
Funding
None.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
Yuichi Saito reports nothing to disclose. Yoshio Kobayashi reports research grants from Abbott Medical Japan, Japan Lifeline, and Terumo, and honoraria from Abbott Medical Japan, Boston Scientific, and Terumo.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Saito, Y., Kobayashi, Y. Contemporary coronary drug-eluting and coated stents: an updated mini-review (2023). Cardiovasc Interv and Ther 39, 15–17 (2024). https://doi.org/10.1007/s12928-023-00954-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12928-023-00954-7